Clinical Trials
Study of ADI-PEG 20 or Placebo Plus Gem and Doc in Previously Treated Subjects With Leiomyosarcoma (ARGSARC)
Link :
https://www.clinicaltrials.gov/ct2/show/NCT05712694
Status :
RECRUITING
Population : LMS
Description : ADI-PEG 20 (arginine degrading enzyme) or Placebo Plus Gemcitabine and Docetaxel
PI : A. Razak
Centers Opened : TBD
Phase : III
IIST/Pharma : Pharma